ArticleBulletin of the World Health Organization2026
Surveillance of antimicrobial resistance by a global network of WHO collaborating centres.
Article in Bulletin of the World Health Organization, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance remains one of the most pressing threats to health globally, with inappropriate antimicrobial use and inequitable access to quality-assured medicines compounding the challenge. In 2015, the World Health Organization (WHO) launched the Global Antimicrobial Resistance Surveillance System to strengthen global surveillance and provide data to inform responses. In support, in 2016 WHO established the AMR Surveillance and Quality Assessment Collaborating Centres Network, a global group of expert institutions that provide technical support and help WHO Member States build surveillance capacity. Between 2016 and 2025, the Network expanded from 18 to 36 institutions across 20 countries and its technical scope has grown to cover antimicrobial use surveillance, emerging antimicrobial resistance, fungal antimicrobial resistance and national action plans. This paper presents a process evaluation of the network, focusing on its development between 2016 and 2025, its contribution to tackling antimicrobial resistance and the challenges faced. Information from documentation and structured interviews indicate that the network played a central role in developing surveillance standards, strengthening laboratory and epidemiology capacity, and helping countries implement surveillance. Challenges persist: network representation is uneven across geographical regions, coordination of resources is limited, and the network's impact is incompletely documented. To maximize its potential, the network must improve output tracking, expand membership from low- and middle-income countries and create subnetworks for specific topics and regions. The analysis offers lessons on how WHO collaborating centre networks can serve as strategic enablers of actions on global health, provided they are adequately supported and integrated into broader implementation frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.